a Grupo de Investigación en Neurociencias (NeURos), Escuela de Medicina y Ciencias de la Salud, Universidad del Rosario , Bogotá , Colombia.
Ocul Immunol Inflamm. 2018;26(5):807-817. doi: 10.1080/09273948.2018.1483519.
To describe the clinical characteristics, diagnosis, and treatment of VIAU in immunocompromised patients.
A critical review of literature was performed.
Diagnosis and treatment of VIAU in immunocompromised patients may be a challenge due to atypical clinical-courses, severe presentations, and more frequent recurrences. A conclusive diagnosis can be made by aqueous-humour PCR-analysis. Visual prognosis depends on early diagnosis and prompt treatment. Frequent ocular examinations are recommended in HIV patients with CD-4-counts below 100 in order to rule out opportunistic ocular coinfections. It is essential to bear in mind the potential side-effects of therapeutic interventions and consider the possibility of Immune Recovery Uveitis (IRU) in eyes with treated viral retinitis after the initiation of HAART.
Early diagnosis and treatment of VIAU in immunocompromised patients can be achieved with high suspicion, recognizing clinical features, and obtaining specimens for molecular diagnostic testing in order to avoid usually severe ocular morbidity.
描述免疫功能低下患者中 VIAU 的临床特征、诊断和治疗方法。
对文献进行了批判性回顾。
由于不典型的临床病程、严重的表现和更频繁的复发，免疫功能低下患者中 VIAU 的诊断和治疗可能具有挑战性。通过房水 PCR 分析可以做出明确的诊断。视力预后取决于早期诊断和及时治疗。建议 HIV 患者的 CD-4 计数低于 100 时，应进行频繁的眼部检查，以排除机会性眼部合并感染。必须牢记治疗干预的潜在副作用，并考虑在开始 HAART 后，治疗病毒性视网膜炎的眼睛中出现免疫恢复性虹膜炎 (IRU) 的可能性。
通过高度怀疑、识别临床特征和获取用于分子诊断检测的标本，可以在免疫功能低下患者中早期诊断和治疗 VIAU，以避免通常严重的眼部发病率。
